FI910587A0 - Syntetiska polypeptider och antikroppar, vilka haenfoer sig till epstein-barr-virusets nukleaera antigen. - Google Patents

Syntetiska polypeptider och antikroppar, vilka haenfoer sig till epstein-barr-virusets nukleaera antigen.

Info

Publication number
FI910587A0
FI910587A0 FI910587A FI910587A FI910587A0 FI 910587 A0 FI910587 A0 FI 910587A0 FI 910587 A FI910587 A FI 910587A FI 910587 A FI910587 A FI 910587A FI 910587 A0 FI910587 A0 FI 910587A0
Authority
FI
Finland
Prior art keywords
antigen
epstein
synthetic
barr
virusets
Prior art date
Application number
FI910587A
Other languages
English (en)
Other versions
FI102381B1 (fi
FI102381B (fi
Inventor
Gary Rhodes
Richard S Smith
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI910587A0 publication Critical patent/FI910587A0/fi
Application granted granted Critical
Publication of FI102381B1 publication Critical patent/FI102381B1/fi
Publication of FI102381B publication Critical patent/FI102381B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI910587A 1988-08-09 1991-02-07 Epstein-Barrin viruksen tuma-antigeeniin (EBNA) liittyviä synteettisiä polypeptidejä ja menetelmä anti-EBNA-vasta-aineiden tunnistamiseksi k udosnäytteessä FI102381B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23025088 1988-08-09
US07/230,250 US5717065A (en) 1984-08-08 1988-08-09 Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US8903350 1989-08-03
PCT/US1989/003350 WO1990001495A1 (en) 1988-08-08 1989-08-03 Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen

Publications (3)

Publication Number Publication Date
FI910587A0 true FI910587A0 (fi) 1991-02-07
FI102381B1 FI102381B1 (fi) 1998-11-30
FI102381B FI102381B (fi) 1998-11-30

Family

ID=22864499

Family Applications (1)

Application Number Title Priority Date Filing Date
FI910587A FI102381B (fi) 1988-08-09 1991-02-07 Epstein-Barrin viruksen tuma-antigeeniin (EBNA) liittyviä synteettisiä polypeptidejä ja menetelmä anti-EBNA-vasta-aineiden tunnistamiseksi k udosnäytteessä

Country Status (13)

Country Link
US (1) US5717065A (fi)
EP (1) EP0428629B1 (fi)
AT (1) ATE134648T1 (fi)
AU (1) AU643188B2 (fi)
CA (1) CA1340446C (fi)
DE (1) DE68925819T2 (fi)
DK (1) DK175828B1 (fi)
ES (1) ES2018909A6 (fi)
FI (1) FI102381B (fi)
GR (1) GR890100501A (fi)
NO (1) NO309720B1 (fi)
PT (1) PT91397B (fi)
WO (1) WO1990001495A1 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585216A1 (en) * 1989-11-24 1994-03-09 The Council Of The Queensland Institue Of Medical Research Im peptides
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ｅｂｎａ抗体の測定方法および抗ｅｂｎａ抗体測定キット
ATE266728T1 (de) * 1992-09-14 2004-05-15 Biomerieux Bv Epstein-barr virus peptide, und antikörper gegen diese peptide
US5833991A (en) * 1995-04-10 1998-11-10 Cobra Therapeutics, Ltd. Glycine-containing sequences conferring invisibility to the immune system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
US5116725A (en) * 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
WO1990001495A1 (en) 1990-02-22
EP0428629A1 (en) 1991-05-29
AU643188B2 (en) 1993-11-11
GR890100501A (el) 1991-12-30
CA1340446C (en) 1999-03-16
EP0428629B1 (en) 1996-02-28
NO309720B1 (no) 2001-03-19
DK21191D0 (da) 1991-02-07
EP0428629A4 (en) 1991-12-27
PT91397B (pt) 1995-05-04
PT91397A (pt) 1990-03-08
NO910479L (no) 1991-04-05
ES2018909A6 (es) 1991-05-16
US5717065A (en) 1998-02-10
NO910479D0 (no) 1991-02-07
FI102381B1 (fi) 1998-11-30
DE68925819T2 (de) 1996-10-02
DK175828B1 (da) 2005-03-14
AU4400089A (en) 1990-03-05
ATE134648T1 (de) 1996-03-15
DE68925819D1 (de) 1996-04-04
DK21191A (da) 1991-04-04
FI102381B (fi) 1998-11-30

Similar Documents

Publication Publication Date Title
HU9202645D0 (en) Synthetic antigenes applicables for detecting antibodies of hepatitis c virus
NZ219113A (en) Hiv peptide containing epitope of the env protein
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
CA2004478A1 (en) Monoclonal antibodies to feline-t-lymphotropic lentivirus
FI910587A0 (fi) Syntetiska polypeptider och antikroppar, vilka haenfoer sig till epstein-barr-virusets nukleaera antigen.
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus